FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Infant nutrition (part 1): Challenges in feeding the first 1,000 days

18 Jun 2018 --- The World Health Organization (WHO) solidly recommends breastfeeding for infants. However, there are situations – medical, situational or personal – that necessitate good quality breast milk substitutes (BMS), such as formulas. In a bid to produce a formula that is closest in composition to human breast milk, manufacturers face a range of unique R&D challenges. In this two-part series on Infant Nutrition, NutritionInsight speaks to a number of key suppliers and experts about these challenges.

Nutrition & Health News

US consumer group to Quorn: “Mycoprotein can be unsafe”

15 Jun 2018 --- The Center for Science in the Public Interest (CSPI) claims in a new report that Quorn’s mycoprotein ingredient has been linked to severe allergic reactions and gastrointestinal symptoms. However, NutritionInsight spoke to a Quorn spokesperson on the issue, who stated that they “challenge the scientific validity” of the claims. The company will, however, update packaging information to flag possible sensitivities that people may have to mycoprotein, which is derived from mold and forms the basis of Quorn's meat-alternative products.

Nutrition & Health News

“Dietary fibers” classification: US FDA green lights eight ingredients

15 Jun 2018 --- The US Food and Drug Administration (FDA) has issued guidance which identifies eight specific fibers that can be classified as “dietary fibers” on the upcoming Nutrition Facts Label, marking the end of two years of uncertainty for manufacturers. In 2016, the FDA initially announced a new regulatory definition for dietary fiber and stated that to be considered a source of fiber, isolated or synthetic non-digestible carbohydrates must have a demonstrated physiological health benefit.

Nutrition & Health News

Non-GMO certification for all-natural caffeine: InnovaTea

11 Jun 2018 – Nutriscience Innovations, supplier of nutritional ingredients and functional raw materials, has received confirmation of non-GMO Project Verification (NGPV) for its InnovaTea Natural Caffeine (98 percent from tea), from the non-GMO project.

Nutrition & Health News

US FDA issues warnings to companies illegally selling concentrated caffeine products

07 Jun 2018 --- The US Food and Drug Administration (FDA) has issued warning letters to the parties responsible for liquidcaffeine.com and Dual Health Body and Mind for illegally selling certain highly concentrated caffeine products. The FDA considers these products to be a threat to public health. The recipients of the warning letters have 15 days to notify the agency about how they have addressed the violations and will prevent them from recurring. If the companies fail to promptly correct these violations, the FDA announced it may take additional action, such as seizure and/or injunction.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html